Pat Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared a post on X:
“The 2nd USA: Saudi Biotech Alliance summit to be held this month in Rhiyadh – this time a sharing of all the combinations of Anktiva and NK cell therapy with oncology thought leaders and leadership in Saudi and setting the launch of Anktiva with NKcell therapy- immunotherapy 2.0. Really exciting to share our decades of work and expand the Bioshield indications.
The clinical trial results validating Nant Cancer vaccine patent, now the Bioshield, will be shared across multiple tumor types from decades of trials across breast to lung to prostate to GBM to Colon cancer. 2026 is a decade since I filed this patent on June 2016.
The NANT Cancer Vaccine (The Cancer BioShield Platform) is now in full scale development at Immunity Bio. Finally, the drive to memory NK and T cells for long-term survival is being proven. This figure is another representation of the drawing in 2016 of my mind map since 1990. Reversing lymphopenia matters.”
More posts featuring T-Cell on OncoDaily.
